MANKIND
Invest Now
Start SIP in
MANKIND
Performance
- Low
- ₹2,547
- High
- ₹2,610
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,580
- Previous Close₹2,573
- Volume352,051
Investment Returns
- Over 1 Month -0.67%
- Over 3 Month + 7.51%
- Over 6 Month -1.3%
- Over 1 Year + 21.43%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 51.8
- PEG Ratio
- 2.9
- Market Cap Cr
- 105,793
- P/B Ratio
- 10
- Average True Range
- 82.48
- EPS
- 49.48
- Dividend Yield
- 0
- MACD Signal
- 23.58
- RSI
- 58.81
- MFI
- 49.67
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,564.20
-8.5
(-0.33%)

-
- Bearish Moving Average 0
-
- Bullish Moving Average 16
- 20 Day
- ₹2,496.71
- 50 Day
- ₹2,464.16
- 100 Day
- ₹2,470.98
- 200 Day
- ₹2,435.39
Resistance and Support
2573.6
- R3 2,664.00
- R2 2,637.00
- R1 2,600.60
- S1 2,537.20
- S2 2,510.20
- S3 2,473.80
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-05-21 | Audited Results | |
2025-01-23 | Quarterly Results | |
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,564 As on 20 May, 2025 | 04:25
The Market Cap of Mankind Pharma is ₹105793.4 Cr As on 20 May, 2025 | 04:25
The P/E ratio of Mankind Pharma is 51.8 As on 20 May, 2025 | 04:25
The PB ratio of Mankind Pharma is 10 As on 20 May, 2025 | 04:25
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.